Preclinical and clinical development of siRNA-based therapeutics
about
Lipid nanoparticles for targeted siRNA delivery - going from bench to bedsideSelection and Biosensor Application of Aptamers for Small MoleculesExosome-mediated small RNA delivery for gene therapyThe Research and Applications of Quantum Dots as Nano-Carriers for Targeted Drug Delivery and Cancer TherapyBioengineering of noncoding RNAs for research agents and therapeuticssiRNA Versus miRNA as Therapeutics for Gene SilencingOligonucleotide Therapies: The Past and the PresentZikaVR: An Integrated Zika Virus Resource for Genomics, Proteomics, Phylogenetic and Therapeutic AnalysisDelivery of RNAi Therapeutics to the Airways-From Bench to BedsideRNA therapeutics: RNAi and antisense mechanisms and clinical applicationsmiR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.siRNAmod: A database of experimentally validated chemically modified siRNAsΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung CancerIn Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs).Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy.DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencingLong noncoding RNAs in prostate cancer: overview and clinical implications.The delivery of therapeutic oligonucleotidesBioengineered non-coding RNA agent (BERA) in action.Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis.Recent Advances in Upconversion Nanoparticles-Based Multifunctional Nanocomposites for Combined Cancer Therapy.Oligonucleotide therapeutics: chemistry, delivery and clinical progress.Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicinesLong and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges.Small Players Ruling the Hard Game: siRNA in Bone Regeneration.Inhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools.Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes.Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery.Current progress on microRNAs-based therapeutics in neurodegenerative diseases.Smart micelleplexes as a new therapeutic approach for RNA delivery.Therapeutic Potentials of Noncoding RNAs: Targeted Delivery of ncRNAs in Cancer Cells.Non-coding RNAs as drug targets.The bright side of dark matter: lncRNAs in cancerFunctional peptides for siRNA delivery.Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.Engineered Hydrogels for Local and Sustained Delivery of RNA-Interference Therapies.Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.
P2860
Q26741449-8138F595-2C4F-4DE8-8888-923355993E14Q26744467-091D8E94-1958-4136-9EC2-61F11F0CEAE3Q26747740-A8F32637-1500-4683-9C88-FDC7020F0D42Q26752676-DD62D71E-1D75-4ACA-A7EC-F592B301CD54Q26772092-F0C43A90-ED66-46EF-AEB9-5CEE83008D76Q26786876-9BCF5CB2-059F-4BE9-A44A-446B026F1159Q27002403-2AD69D1C-D673-4B25-988F-9D73F4FA77F6Q27468686-8D102533-94AE-4108-86CE-042440CA6527Q28067306-E2ADE60F-5AEA-4BF3-845C-F469F0D80D85Q28829240-AC78348C-8257-44D4-809B-0EBD5B5EE112Q33804175-6FF5C36F-79AC-4807-9723-5835533E977CQ34511095-55440D90-7372-4D6B-9B33-7D56A1F1E270Q36051831-C2BCC12F-DA5B-4D87-86F5-09A50168A7A3Q36192506-E96A4769-9683-4085-899B-A0AA4666F9A4Q36268420-00A0458E-0283-4C81-AF85-01D18390271DQ36382827-8BF6552C-EBCB-4D88-A20E-F73B57A24081Q36510849-F12F4495-D471-4B3C-B115-74D2012CB521Q37031903-CDED45BA-8D8F-48C6-A20E-204A522EE211Q37113177-8F2099BF-3A9D-4EB5-897F-E467597ABFF8Q37210936-5A2C48A7-B4EE-4178-B5B9-0FDF89597DB5Q37391959-513FDF63-F8A8-48AA-8C13-A4250275ACADQ38575287-7B6CDC87-5858-4531-8316-8A37A3B36B6DQ38617240-648B2CFE-A4B6-4A72-B170-906894F223ACQ38618638-E381A149-85C3-4236-8C75-F58D309856D1Q38674444-C335B16E-6759-4E3D-982A-5EA46D79A5E7Q38734500-790EFDE1-98B6-4A92-98B0-F76D5A419EAEQ38738927-6FA49BC2-4BFE-4BBA-B01F-361F011FA458Q38770194-6DDCA0E4-52FF-4496-9BA2-1D43D976D429Q38780952-0FBC910E-D1A6-4348-A08F-E636B5EEA09EQ38788622-C539C7C8-6A8E-4EE7-9003-2B1E82F8FA26Q38791303-4D70116B-8DB8-4E2D-912E-93B6F0BE3FC4Q38840111-E119100E-1FEC-4B06-A24E-AB044122EB2FQ38885511-5EAB110D-C76A-47F7-A986-B114A8DFD85AQ38904908-68103A86-6496-4368-9922-75D342972202Q38915010-538D0687-F1C0-4BF9-B930-762EAB310944Q38928987-059B8FD4-5506-4E99-9112-A5337768801DQ38943053-929560A6-9E11-4D30-948E-81838C316882Q39038930-21CA43AF-09AC-4AA8-9536-310E69FFCC56Q39096514-C75AAC05-1A84-41EC-B8D5-F3415EAC0290Q39102784-5FFA6054-376B-48BD-8A3E-57CF5A222899
P2860
Preclinical and clinical development of siRNA-based therapeutics
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Preclinical and clinical development of siRNA-based therapeutics
@ast
Preclinical and clinical development of siRNA-based therapeutics
@en
Preclinical and clinical development of siRNA-based therapeutics
@nl
type
label
Preclinical and clinical development of siRNA-based therapeutics
@ast
Preclinical and clinical development of siRNA-based therapeutics
@en
Preclinical and clinical development of siRNA-based therapeutics
@nl
prefLabel
Preclinical and clinical development of siRNA-based therapeutics
@ast
Preclinical and clinical development of siRNA-based therapeutics
@en
Preclinical and clinical development of siRNA-based therapeutics
@nl
P2093
P2860
P3181
P1476
Preclinical and clinical development of siRNA-based therapeutics
@en
P2093
Anil K. Sood
Bulent Ozpolat
Gabriel Lopez-Berestein
Gulnihal Ozcan
Robert L. Coleman
P2860
P304
P3181
P356
10.1016/J.ADDR.2015.01.007
P407
P577
2015-06-29T00:00:00Z